Eli Lilly — May 1, 2025 release

2025 Guidance Earnings per share (reported) $20.17 to $21.67 Amortization of intangible assets .44 Asset impairment, restructuring, and other special charges .03 Net losses on investments in equity securities .13 Earnings per share (non-GAAP) $20.78 to $22.28 Numbers may not add due to rounding 2 The Company defines performance margin as gross margin less R&D, Marketing, Selling, and Administrative and Asset Impairment, Restructuring and Other Charges divided by revenue 7 The following table summarizes the company's updated 2025 financial guidance: Prior Updated (1) (2) (3) Revenue $58.0 to $61.0 billion Unchanged Performance Margin (4) (reported) 40.5% to 42.5% Unchanged (non-GAAP) 41.5% to 43.5% Unchanged Other Income/(Expense) (reported) ($700) to ($600) million ($850) to ($750) million Other Income/(Expense) (non-GAAP) ($700) to ($600) million Unchanged Tax Rate Approx. 16% Approx. 17% Earnings per Share (reported) $22.05 to $23.55 $20.17 to $21.67 Earnings per Share (non-GAAP) $22.50 to $24.00 $20.78 to $22.28 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) Guidance includes acquired IPR&D charges through Q1 2025 of $1.57 billion or $1.72 on a per share basis. Guidance does not include acquired IPR&D either incurred, or expected to be incurred, after Q1 2025. (3) This guidance is based on the existing tariff and trade environment as of May 1, 2025, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business. (4) The Company defines performance margin as gross margin less R&D, Marketing, Selling, and Administrative, and Asset Impairment, Restructuring and Other Charges divided by revenue. 8 Webcast of Conference Call As previously announced, investors and the general public can